Dual antiplatelet therapy — Research & Evidence

Q: What does the research say about Dual antiplatelet therapy?

The scientific consensus on Dual antiplatelet therapy is unknown. No claims extracted for this topic Based on 0 analyzed claims.

What does the research say about Dual antiplatelet therapy?

Unknown pathwayBased on 0 claims ( agreements, contradictions)

No claims extracted for this topic

Clinical questions in Dual antiplatelet therapy

Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.

Does dual antiplatelet therapy vs placebo improve outcomes in Embolic and thrombotic events (SMQ)?

Low Certainty+ Favors benefit

dual antiplatelet therapy vs placebo · Cardiac Output

24 studies · 56,150 patients· 42 estimates

Does clopidogrel vs ticagrelor improve outcomes in Acute Coronary Syndrome?

Low Certainty− Favors harm

clopidogrel vs ticagrelor · Cardiac Output

15 studies · 148,122 patients· 27 estimates

Does vitamin k antagonist vs antiplatelet improve outcomes in Major bleeding - TIMI classification?

Low Certainty− Favors harm

vitamin k antagonist vs antiplatelet · Major Bleeding

5 studies · 20,372 patients· 5 estimates

Does clopidogrel vs aspirin improve outcomes in Non ST segment elevation acute coronary syndrome?

Low Certainty− Favors harm

clopidogrel vs aspirin · Cardiac Output

15 studies · 3,915 patients· 73 estimates

Does antiplatelet vs placebo improve outcomes in Coronary artery stent (device)?

Low Certainty− Favors harm

antiplatelet vs placebo · Cardiac Output

12 studies · 2,413 patients· 127 estimates

Does oral antiplatelet agents vs placebo improve outcomes in Acute Coronary Syndrome?

Low Certainty− Favors harm

oral antiplatelet agents vs placebo · Cardiac Output

3 studies· 13 estimates

Does antiplatelet agents vs intravenous thrombolysis improve outcomes in Ischemic stroke?

Low Certainty− Favors harm

antiplatelet agents vs intravenous thrombolysis · Stroke Hospitalization

3 studies· 6 estimates

Evidence brief: Dual antiplatelet therapy

Dual antiplatelet therapy (also known as DAPT, dual antiplatelet, P2Y12 inhibitors). DAPT duration and strategies post-PCI

Synapse tracks 7 specific clinical questions in Dual antiplatelet therapy, each synthesized independently from its own trial evidence. They include: "Does dual antiplatelet therapy vs placebo improve outcomes in Embolic and thrombotic events (SMQ)?"; "Does clopidogrel vs ticagrelor improve outcomes in Acute Coronary Syndrome?"; "Does vitamin k antagonist vs antiplatelet improve outcomes in Major bleeding - TIMI classification?"; "Does clopidogrel vs aspirin improve outcomes in Non ST segment elevation acute coronary syndrome?"; "Does antiplatelet vs placebo improve outcomes in Coronary artery stent (device)?".

As of 2026-06-25, the scientific consensus on Dual antiplatelet therapy is unknown. No claims extracted for this topic

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a30fb42209bc31dca33f.

Deterministic synthesis from Synapse's enriched corpus — 128 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

Follow the latest Dual antiplatelet therapy research

Explore every Dual antiplatelet therapy paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search Dual antiplatelet therapy papers